Literature DB >> 7260546

Single-drug chemotherapy with 5-FU and adriamycin in metastatic bladder cancer.

S D Fosså, T E Gudmundsen.   

Abstract

Either 5-fluorouracil (5-FU) or Adriamycin was used as single-drug treatment in 10 and 15 patients respectively with measurable metastatic bladder carcinoma. In the 5-FU group there were one complete and 2 partial remissions. Six partial remissions were observed in patients treated with Adriamycin. The duration of the remissions was usually short. Gastrointestinal and haematological side effects were more pronounced in the Adriamycin group. The results are discussed in relation to other reports on cytostatic treatment of bladder carcinoma, with emphasis on general problems concerning chemotherapy of this disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7260546     DOI: 10.1111/j.1464-410x.1981.tb03188.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  8 in total

Review 1.  Invasive bladder cancer--possible future treatment considerations.

Authors:  R A Gardiner
Journal:  Urol Res       Date:  1986

2.  Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.

Authors:  A Maru; H Akaza; S Isaka; K Koiso; T Kotake; T Machida; Y Matsumura; Y Nakagami; T Niijima; K Obata
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.

Authors:  K Obata; Y Ohashi; H Akaza; S Isaka; S Kagawa; K Koiso; T Kotake; T Machida; Y Matsumura; T Niijima
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.

Authors:  T Kotake; M Usami; T Miki; M Kuroda; K Obata; M Osafune; H Fujioka; Y Takasugi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group.

Authors:  T Ueda; S Naito; A Iguchi; K Sagiyama; Y Osada; A Ariyoshi; T Omoto; J Kumazawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Chemotherapy of advanced transitional-cell carcinoma of the bladder.

Authors:  R S Miller; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Results of systemic chemotherapy of advanced bladder carcinomas (phase II study).

Authors:  G Stadie; A Möller; H Müller; D Katenkamp; H Urban; D Kob
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

8.  Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results.

Authors:  T Ueda; A Iguchi; K Sagiyama; Y Osada; A Ariyoshi; T Omoto; J Kumazawa
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.